MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel [Yahoo! Finance]
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia (NASDAQ:MTVA) had its price target raised by analysts at HC Wainwright from $12.00 to $40.00. They now have a "buy" rating on the stock.